Extracellular vesicles: emerging therapeutic agents for liver fibrosis DOI Open Access
Giulia Chiabotto,

Armina Semnani,

Elena Ceccotti

et al.

Extracellular Vesicles and Circulating Nucleic Acids, Journal Year: 2025, Volume and Issue: 6(2), P. 216 - 44

Published: May 7, 2025

Liver fibrosis is a progressive condition characterized by excessive scar tissue buildup, leading to impaired liver function and potentially cirrhosis. Despite advancements in treatment strategies, effective anti-fibrotic therapies remain an urgent unmet need. Recent research has identified extracellular vesicles (EVs) as promising therapeutic agents due their ability mediate intercellular communication regulate key fibrotic pathways. This review aims provide comprehensive overview of the potential EVs different vitro vivo models hepatic fibrosis, focusing on natural effects recent engineering for enhanced efficacy. can be derived from various cellular sources, including mesenchymal stromal cells (MSCs) liver-resident cells. Biological materials, serum, breast milk, bacteria, plants, also serve EV sources. Among these, MSC-EVs stand out potential, which significantly through preconditioning with inflammatory signals, pharmacological agents, or genetic improve quality Engineering techniques have further expanded applications, enabling use precise drug-delivery vehicles. Approaches such loading compounds, designing customized EVs, creating EV-liposome hybrids enable targeted delivery activated stellate (HSCs), central drivers progression. These strategies enhance efficacy EV-based treatments. Both engineered critical pathways development, activation HSCs, modulation pro-fibrotic genes, matrix deposition, programmed cell death. Additionally, modulate immune responses, fostering microenvironment conducive repair regeneration. Combining regenerative properties innovative provides highly targeted, approaches restore address need chronic disease therapies.

Language: Английский

Extracellular vesicles: emerging therapeutic agents for liver fibrosis DOI Open Access
Giulia Chiabotto,

Armina Semnani,

Elena Ceccotti

et al.

Extracellular Vesicles and Circulating Nucleic Acids, Journal Year: 2025, Volume and Issue: 6(2), P. 216 - 44

Published: May 7, 2025

Liver fibrosis is a progressive condition characterized by excessive scar tissue buildup, leading to impaired liver function and potentially cirrhosis. Despite advancements in treatment strategies, effective anti-fibrotic therapies remain an urgent unmet need. Recent research has identified extracellular vesicles (EVs) as promising therapeutic agents due their ability mediate intercellular communication regulate key fibrotic pathways. This review aims provide comprehensive overview of the potential EVs different vitro vivo models hepatic fibrosis, focusing on natural effects recent engineering for enhanced efficacy. can be derived from various cellular sources, including mesenchymal stromal cells (MSCs) liver-resident cells. Biological materials, serum, breast milk, bacteria, plants, also serve EV sources. Among these, MSC-EVs stand out potential, which significantly through preconditioning with inflammatory signals, pharmacological agents, or genetic improve quality Engineering techniques have further expanded applications, enabling use precise drug-delivery vehicles. Approaches such loading compounds, designing customized EVs, creating EV-liposome hybrids enable targeted delivery activated stellate (HSCs), central drivers progression. These strategies enhance efficacy EV-based treatments. Both engineered critical pathways development, activation HSCs, modulation pro-fibrotic genes, matrix deposition, programmed cell death. Additionally, modulate immune responses, fostering microenvironment conducive repair regeneration. Combining regenerative properties innovative provides highly targeted, approaches restore address need chronic disease therapies.

Language: Английский

Citations

0